Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.

Background: Diffuse cutaneous leishmaniasis (DCL), although rare, is profoundly incapacitating. At present there is no successful treatment for this progressive protozoan infection, which is associated with the absence of specific cell-mediated immunity (CMI) to Leishmania. This disease shares features with visceral leishmaniasis (VL), including specific CMI inactivity during active disease and a heavy parasitic burden, but VL responds well to treatment.

Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report.

Severe mucocutaneous (MCL) and diffuse (DCL) forms of American cutaneous leishmaniasis (ACL) are infrequent in Venezuela. Chemotherapy produces only transitory remission in DCL, and occasional treatment failures are observed in MCL. We have evaluated therapy with an experimental vaccine in patients with severe leishmaniasis.

Specific inhibitory effect of 3-deazaneplanocin A against several Leishmania mexicana and L. braziliensis strains.

The growth inhibitory effect of 3-deazaneplanocin A (c3NpcA) was tested against some pathogenic members of the family of American Trypanosomatidae. Under our culture conditions, c3NpcA displayed a strongly and uniformly leishmanistatic effect on all 23 American Leishmania (L. mexicana and L.

Uptake and metabolism of S-adenosyl-L-methionine by Leishmania mexicana and Leishmania braziliensis promastigotes.

Promastigotes of Leishmania mexicana and Leishmania braziliensis incorporate S-adenosyl-L-[3H-methyl]methionine (AdoMet) against a concentration gradient through a saturable system. This concentrative uptake requires metabolic energy and is sensitive to temperature and sulfhydryl reagents such as N-ethyl maleimide. Intracellular AdoMet exchanges with external AdoMet.

Inhibitory effects of sinefungin and its cyclic analog on the multiplication of Trypanosoma cruzi isolates.

Sinefungin and its cyclic analog were evaluated in vitro for activity against the multiplication of Trypanosoma cruzi. When either drug was tested for eight days on twelve T. cruzi epimastigote isolates, an 800-fold difference in drug sensitivity was found.